Medical Therapy in Chronic Refractory Ulcerative Colitis: When Enough Is Enough

Abstract

Despite significant improvements in the management of ulcerative colitis (UC) in parallel with the evolution of therapeutic targets and novel biologics and small molecules, a subset of medically refractory patients still requires colectomy. Recent population-based studies demonstrate a trend toward a decrease in the rates of surgery for UC patients in the biological era, although the potential of disease modification with these agents is still debated. As the concept of irreversible bowel damage is underexplored in UC, refractory patients can be exposed to multiple treatments losing optimal timing for surgery and further developing complications such as dysplasia/cancer, dysmotility, microcolon, and other functional abnormalities. This review aims to discuss the concept of disease progression in UC, explore the limitations of medical treatment in refractory UC patients, and propose the application of a three-step algorithm that allows timely indication for surgery in clinical practice.

Keywords

ulcerative colitis - colectomy - biologics - tofacitinib

Publikationsverlauf

Artikel online veröffentlicht:
17. Januar 2022

• References

• 1 Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011; 140 (06) 1785-1794
• 2 Allen PB, Gower-Rousseau C, Danese S, Peyrin-Biroulet L. Preventing disability in inflammatory bowel disease. Therap Adv Gastroenterol 2017; 10 (11) 865-876
• 3 Rutgeerts P, Sandborn WJ, Feagan BG. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353 (23) 2462-2476
• 4 Lopez A, Ford AC, Colombel J-F, Reinisch W, Sandborn WJ, Peyrin-Biroulet L. Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: meta-analysis of placebo-controlled trials. Dig Liver Dis 2015; 47 (05) 356-364
• 5 Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S. AGA Institute Clinical Guidelines Committee. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology 2020; 158 (05) 1450-1461
• 6 Feagan BG, Rutgeerts P, Sands BE. et al; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369 (08) 699-710
• 7 Sandborn WJ, Su C, Sands BE. et al; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017; 376 (18) 1723-1736
• 8 Sands BE, Sandborn WJ, Panaccione R. et al; UNIFI Study Group. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2019; 381 (13) 1201-1214
• 9 Ungaro R, Colombel J-F, Lissoos T, Peyrin-Biroulet L. A treat-to-target update in ulcerative colitis: a systematic review. Am J Gastroenterol 2019; 114 (06) 874-883
• 10 Frolkis AD, Dykeman J, Negrón ME. et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology 2013; 145 (05) 996-1006
• 11 Gordon IO, Agrawal N, Willis E. et al. Fibrosis in ulcerative colitis is directly linked to severity and chronicity of mucosal inflammation. Aliment Pharmacol Ther 2018; 47 (07) 922-939
• 12 Torres J, Billioud V, Peyrin-Biroulet L, Colombel J-F. Ulcerative colitis as a sole mucosal disease: another misunderstanding?. Gut 2012; 61 (04) 633
• 13 Le Berre C, Ananthakrishnan AN, Danese S, Singh S, Peyrin-Biroulet L. Ulcerative colitis and Crohn's disease have similar burden and goals for treatment. Clin Gastroenterol Hepatol 2020; 18 (01) 14-23
• 14 Fumery M, Singh S, Dulai PS, Gower-Rousseau C, Peyrin-Biroulet L, Sandborn WJ. Natural history of adult ulcerative colitis in population-based cohorts: a systematic review. Clin Gastroenterol Hepatol 2018; 16 (03) 343-356.e3
• 15 Torres J, Billioud V, Sachar DB, Peyrin-Biroulet L, Colombel J-F. Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis 2012; 18 (07) 1356-1363
• 16 Macaluso FS, Cavallaro F, Felice C. et al. Risk factors and timing for colectomy in chronically active refractory ulcerative colitis: a systematic review. Dig Liver Dis 2019; 51 (05) 613-620
• 17 Rutter MD, Saunders BP, Wilkinson KH. et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 2004; 53 (12) 1813-1816
• 18 Bernardini N, Segnani C, Ippolito C. et al. Immunohistochemical analysis of myenteric ganglia and interstitial cells of Cajal in ulcerative colitis. J Cell Mol Med 2012; 16 (02) 318-327
• 19 Beaugerie L, Itzkowitz SH. Cancers complicating inflammatory bowel disease. N Engl J Med 2015; 372 (15) 1441-1452
• 20 Jess T, Loftus Jr EVJ, Velayos FS. et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology 2006; 130 (04) 1039-1046
• 21 Winther KV, Jess T, Langholz E, Munkholm P, Binder V. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2004; 2 (12) 1088-1095
• 22 Stewénius J, Adnerhill I, Anderson H. et al. Incidence of colorectal cancer and all cause mortality in non-selected patients with ulcerative colitis and indeterminate colitis in Malmö, Sweden. Int J Colorectal Dis 1995; 10 (02) 117-122
• 23 Söderlund S, Brandt L, Lapidus A. et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology 2009; 136 (05) 1561-1567 , quiz 1818–1819
• 24 Castaño-Milla C, Chaparro M, Gisbert JP. Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther 2014; 39 (07) 645-659
• 25 Olén O, Erichsen R, Sachs MC. et al. Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study. Lancet 2020; 395 (10218): 123-131
• 26 Cremer A, Demetter P, De Vos M. et al; Belgian Inflammatory Bowel Disease Research and Development (BIRD) Group. Risk of development of more-advanced lesions in patients with inflammatory bowel diseases and dysplasia. Clin Gastroenterol Hepatol 2020; 18 (07) 1528-1536.e5
• 27 Damas OM, Abreu MT. Are patients with ulcerative colitis still at increased risk of colon cancer?. Lancet 2020; 395 (10218): 92-94
• 28 Gupta RB, Harpaz N, Itzkowitz S. et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007; 133 (04) 1099-1105 , quiz 1340–1341
• 29 Flores BM, O'Connor A, Moss AC. Impact of mucosal inflammation on risk of colorectal neoplasia in patients with ulcerative colitis: a systematic review and meta-analysis. Gastrointest Endosc 2017; 86 (06) 1006-1011.e8
• 30 Olivera P, Spinelli A, Gower-Rousseau C, Danese S, Peyrin-Biroulet L. Surgical rates in the era of biological therapy: up, down or unchanged?. Curr Opin Gastroenterol 2017; 33 (04) 246-253
• 31 Kaplan GG, Seow CH, Ghosh S. et al. Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Am J Gastroenterol 2012; 107 (12) 1879-1887
• 32 Parragi L, Fournier N, Zeitz J. et al; Swiss IBD Cohort Study Group. Colectomy rates in ulcerative colitis are low and decreasing: 10-year follow-up data from the Swiss IBD cohort study. J Crohn's Colitis 2018; 12 (07) 811-818
• 33 Uchino M, Ikeuchi H, Hata K. et al. Changes in the rate of and trends in colectomy for ulcerative colitis during the era of biologics and calcineurin inhibitors based on a Japanese nationwide cohort study. Surg Today 2019; 49 (12) 1066-1073
• 34 Ma C, Beilman CL, Huang VW. et al. Similar clinical and surgical outcomes achieved with early compared to late anti-TNF induction in mild-to-moderate ulcerative colitis: a retrospective cohort study. Can J Gastroenterol Hepatol 2016; 2016: 2079582
• 35 Han M, Jung YS, Cheon JH, Park S. Similar clinical outcomes of early and late anti-TNF initiation for ulcerative colitis: a nationwide population-based study. Yonsei Med J 2020; 61 (05) 382-390
• 36 Stange EF, Travis SPL, Vermeire S. et al; European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006; 55 (1, Suppl 1): i1-i15
• 37 Harbord M, Eliakim R, Bettenworth D. et al; European Crohn's and Colitis Organisation [ECCO]. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. part 2: current management. J Crohn's Colitis 2017; 11 (07) 769-784
• 38 Le Berre C, Roda G, Nedeljkovic Protic M, Danese S, Peyrin-Biroulet L. Modern use of 5-aminosalicylic acid compounds for ulcerative colitis. Expert Opin Biol Ther 2020; 20 (04) 363-378
• 39 Damião AOMC, de Azevedo MFC, Carlos AS, Wada MY, Silva TVM, Feitosa FC. Conventional therapy for moderate to severe inflammatory bowel disease: a systematic literature review. World J Gastroenterol 2019; 25 (09) 1142-1157
• 40 Narula N, Marshall JK, Colombel J-F. et al. Systematic review and meta-analysis: infliximab or cyclosporine as rescue therapy in patients with severe ulcerative colitis refractory to steroids. Am J Gastroenterol 2016; 111 (04) 477-491
• 41 Shah SC, Naymagon S, Cohen BL, Sands BE, Dubinsky MC. There is significant practice pattern variability in the management of the hospitalized ulcerative colitis patient at a tertiary care and IBD referral center. J Clin Gastroenterol 2018; 52 (04) 333-338
• 42 Herfarth HH, Long MD, Isaacs KL. Methotrexate: underused and ignored?. Dig Dis 2012; 30 (Suppl. 03) 112-118
• 43 Chhibba T, Ma C. Is there room for immunomodulators in ulcerative colitis?. Expert Opin Biol Ther 2020; 20 (04) 379-390
• 44 Carbonnel F, Colombel JF, Filippi J. et al; European Crohn's and Colitis Organisation, Groupe d'Étude Thérapeutique des Affections Inflammatoires Digestives. Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis. Gastroenterology 2016; 150 (02) 380-8.e4
• 45 Herfarth H, Barnes EL, Valentine JF. et al; Clinical Research Alliance of the Crohn's and Colitis Foundation. Methotrexate is not superior to placebo in maintaining steroid-free response or remission in ulcerative colitis. Gastroenterology 2018; 155 (04) 1098-1108.e9
• 46 Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol 2019; 114 (03) 384-413
• 47 Bressler B, Marshall JK, Bernstein CN. et al; Toronto Ulcerative Colitis Consensus Group. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology 2015; 148 (05) 1035-1058.e3
• 48 Lamb CA, Kennedy NA, Raine T. et al; IBD guidelines eDelphi consensus group. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019; 68 (Suppl. 03) s1-s106
• 49 Reinisch W, Sandborn WJ, Hommes DW. et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60 (06) 780-787
• 50 Sandborn WJ, van Assche G, Reinisch W. et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142 (02) 257-65.e1 , 3
• 51 Sandborn WJ, Feagan BG, Marano C. et al; PURSUIT-Maintenance Study Group. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146 (01) 96-109.e1
• 52 Bressler B, Yarur A, Kopylov U. et al. 638 clinical effectiveness of first-line anti-TNF therapies and second-line anti-TNF therapy post-vedolizumab discontinuation in patients with ulcerative colitis or Crohn's disease. Am J Gastroenterol 2019; 114: S373
• 53 Sands BE, Peyrin-Biroulet L, Loftus Jr EVJ. et al; VARSITY Study Group. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med 2019; 381 (13) 1215-1226
• 54 Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis. Clin Gastroenterol Hepatol 2020; 18 (10) 2179-2191.e6
• 55 Danese S. New drugs in the ulcerative colitis pipeline: Prometheus unbound. Gastroenterology 2020; 158 (03) 467-470
• 56 Misselwitz B, Juillerat P, Sulz MC, Siegmund B, Brand S. Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. Emerging treatment options in inflammatory bowel disease: Janus kinases, stem cells, and more. Digestion 2020; 101 (Suppl. 01) 69-82
• 57 Neufert C, Neurath MF, Atreya R. Rationale for IL-36 receptor antibodies in ulcerative colitis. Expert Opin Biol Ther 2020; 20 (04) 339-342
• 58 Glassner K, Oglat A, Duran A. et al. The use of combination biological or small molecule therapy in inflammatory bowel disease: a retrospective cohort study. J Dig Dis 2020; 21 (05) 264-271
• 59 Yu H, MacIsaac D, Wong JJ. et al. Market share and costs of biologic therapies for inflammatory bowel disease in the USA. Aliment Pharmacol Ther 2018; 47 (03) 364-370
• 60 Taxonera C, Olivares D, Mendoza JL, Díaz-Rubio M, Rey E. Need for infliximab dose intensification in Crohn's disease and ulcerative colitis. World J Gastroenterol 2014; 20 (27) 9170-9177
• 61 Ochsenkühn T, Tillack C, Szokodi D, Janelidze S, Schnitzler F. Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis. United European Gastroenterol J 2020; 8 (01) 91-98
• 62 Peyrin-Biroulet L, Sandborn W, Sands BE. et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 2015; 110 (09) 1324-1338
• 63 Pai RK, Jairath V, Vande Casteele N, Rieder F, Parker CE, Lauwers GY. The emerging role of histologic disease activity assessment in ulcerative colitis. Gastrointest Endosc 2018; 88 (06) 887-898
• 64 Fiocchi C, Iliopoulos D. What's new in IBD therapy: an “omics network” approach. Pharmacol Res 2020; 159: 104886